Tradename: ELEVIDYS

Proper Name: delandistrogene moxeparvovec-rokl

Indication: Indicated for treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene.                

Approval Date: 06/22/2023

Manufacturer: Sarepta Therapeutics, Inc.


Leave a Reply

Your email address will not be published. Required fields are marked *